EN Official Journal of the European Union C 356/7

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2011

2014/C 356/06

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July - 31 December 2011, at their meeting on 15 June 2012:

Annex I List of new marketing authorisations Annex II List of renewed marketing authorisations Annex III List of extended marketing authorisations Annex IV List of withdrawn marketing authorisations Annex V List of suspended marketing authorisations

ANNEX I List of new marketing authorisations The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July- 31 December 2011: EU-Number Product Country Date of authorisation EU/1/09/543/001-002 Cayston (1) Liechtenstein 31.10.2011 EU/1/10/642/001-004 Ibandronic Acid Teva Norway 23.8.2011 EU/1/10/649/001-016 Clopidogrel Teva Pharma B.V Norway 19.7.2011 EU/1/10/649/001-016 Clopidogrel Teva Pharma B.V. Liechtenstein 31.8.2011 EU/1/10/652/001-003 TOBI Podhaler Liechtenstein 31.8.2011 EU/1/10/652/001-003 TOBI Podhaler Norway 17.8.2011 EU/1/10/652/001-003 TOBI Podhaler Iceland 9.8.2011 EU/1/10/654/001-004 Leflunomide ratiopharm Norway 25.8.2011 EU/1/10/660/001-002 Potactasol Norway 24.8.2011 EU/1/10/661/001-002 Fluenz Norway 23.8.2011 EU/1/11/672/001-006 Xeplion Liechtenstein 31.10.2011 EU/1/11/683/001-080 Sprimeo HCT Liechtenstein 31.8.2011 EU/1/11/683/001-080 Sprimeo HCT Norway 22.8.2011 EU/1/11/683/001-080 Sprimeo HCT Iceland 10.8.2011 EU/1/11/685/001-005 Ibandronic acid Sandoz Liechtenstein 31.8.2011 EU/1/11/685/001-005 Ibandronic acid Sandoz Iceland 18.8.2011 EU/1/11/689/001-002 IOA Liechtenstein 31.12.2011 EU/1/11/689/001-002 IOA Norway 6.12.2011 EU/1/11/689/001-002 Ioa Iceland 25.11.2011 EU/1/11/690/001-002 Zoely Liechtenstein 31.8.2011 EU/1/11/690/001-002 Zoely Norway 18.8.2011 EU/1/11/690/001-002 Zoely Iceland 9.8.2011 EU/1/11/691/001-005 Eliquis Iceland 8.8.2011 EU/1/11/693/001-016 Rivastigmin Actavis Norway 19.8.2011 EU/1/11/694/001-002 Nulojix Liechtenstein 31.8.2011 EU/1/11/694/001-002 Nulojix Norway 1.8.2011 EU/1/11/694/001-002 Nulojix Iceland 6.7.2011 EU/1/11/695/001-055 Leganto Liechtenstein 31.8.2011 EU/1/11/695/001-055 Leganto Norway 23.8.2011 EU/1/11/695/001-055 Leganto Iceland 6.7.2011 EU/1/11/696/001-002 Bydureon Norway 5.7.2011 EU/1/11/696/001-002 Bydureon Iceland 6.7.2011 EU/1/11/696/001-002 Bydureon Liechtenstein 31.8.2011 EU/1/11/697/001-012 Temozolomide Sun Liechtenstein 31.8.2011 EU/1/11/697/001-012 Temozolomide SUN Norway 22.8.2011 EU/1/11/697/001-012 Temozolomide SUN Iceland 9.8.2011 EU/1/11/698/001-002 Yervoy Liechtenstein 31.8.2011 EU/1/11/698/001-002 Yervoy Norway 18.8.2011 EU/1/11/698/001-002 Yervoy Iceland 21.7.2011 EU/1/11/699/001-002 Fampyra Liechtenstein 31.8.2011 EU/1/11/699/001-002 Fampyra Norway 23.8.2011 EU/1/11/699/001-002 Fampyra Iceland 9.8.2011 EU/1/11/700/001-002 Benlysta Liechtenstein 31.8.2011 EU/1/11/700/001-002 Benlysta Norway 27.7.2011 EU/1/11/700/001-002 Benlysta Iceland 21.7.2011 EU/1/11/701/001-028 Levetiracetam Teva Liechtenstein 31.10.2011 EU/1/11/701/001-028 Levetiracetam Teva Norway 26.9.2011 EU/1/11/701/001-028 Levetiracetam Teva Iceland 16.9.2011 EU/1/11/702/001-031 Levetiracetam Ratiopharm Liechtenstein 31.10.2011 EU/1/11/702/001-031 Levetiracetam ratiopharm Norway 26.9.2011 EU/1/11/702/001-031 Levetiracetam ratiopharm Iceland 16.9.2011 EU/1/11/703/001-002 Xgeva Liechtenstein 31.8.2011 EU/1/11/703/001-002 Xgeva Norway 15.8.2011 EU/1/11/703/001-002 XGEVA Iceland 21.7.2011 EU/1/11/704/001 Victrelis Liechtenstein 31.8.2011 EU/1/11/704/001 Victrelis Norway 16.8.2011 EU/1/11/704/001 Victrelis Iceland 10.8.2011 EU/1/11/705/001-002 Vibativ Liechtenstein 31.10.2011 EU/1/11/705/001-002 Vibativ Norway 19.9.2011 EU/1/11/705/001-002 Vibativ Iceland 16.9.2011 EU/1/11/706/001-033 Levodopa/Cardidopa/Entacapone Orion Liechtenstein 31.10.2011 EU/1/11/706/001-033 Levodopa/Carbidopa/Entacapone Orion Norway 23.9.2011 EU/1/11/706/001-033 Levodopa/Carbidopa/Entacapone Orion Iceland 14.9.2011 EU/1/11/707/001-011 Trajenta Liechtenstein 31.10.2011 EU/1/11/707/001-011 Trajenta Norway 12.9.2011 EU/1/11/707/001-011 Trajenta Iceland 14.9.2011 EU/1/11/708/001-004 Entacapone Orion Liechtenstein 31.8.2011 EU/1/11/708/001-004 Entacapone Orion Norway 22.9.2011 EU/1/11/708/001-004 Entacapone Orion Iceland 26.8.2011 EU/1/11/709/001-004 Buccolam Norway 27.9.2011 EU/1/11/709/001-03 Buccolam Iceland 1.11.2011 EU/1/11/710/001-007 Votubia Liechtenstein 31.10.2011 EU/1/11/710/001-007 Votubia Norway 15.9.2011 EU/1/11/710/001-007 Votubia Iceland 16.9.2011 EU/1/11/711/001-030 Matever Liechtenstein 31.10.2011 EU/1/11/711/001-030 Matever Iceland 13.10.2011 EU/1/11/712/001-028 Levetiracetam Accord Liechtenstein 31.10.2011 EU/1/11/712/001-028 Levetiracetam Accord Iceland 6.11.2011 EU/1/11/713/001-040 Levetiracetam Actavis Liechtenstein 31.10.2011 EU/1/11/713/001-040 Levetiracetam Actavis Iceland 13.10.2011 EU/1/11/714/001 Zytiga Liechtenstein 31.10.2011 EU/1/11/714/001 Zytiga Norway 26.9.2011 EU/1/11/714/001 Zytiga 250 mg Tafla Iceland 19.9.2011 EU/1/11/715/001-002 Plenadren Liechtenstein 31.12.2011 EU/1/11/715/001-002 Plenadren Norway 25.11.2011 EU/1/11/716/001-005 Eurartesim Liechtenstein 31.12.2011 EU/1/11/716/001-005 Eurartesim Norway 21.12.2011 EU/1/11/716/001-005 Eurartesim Iceland 10.11.2011 EU/1/11/717/001 Vyndaqel Liechtenstein 31.12.2011 EU/1/11/717/001 Vyndaqel Norway 6.12.2011 EU/1/11/717/001 Vyndaqel Iceland 25.11.2011 EU/1/11/718/001-006 Dexdor Liechtenstein 31.10.2011 EU/1/11/718/001-006 Dexdor Norway 11.10.2011 EU/1/11/718/001-006 Dexdor Iceland 30.9.2011 EU/1/11/719/001-060 Telmisartan Teva Pharma Norway 18.10.2011 EU/1/11/719/001-060 Telmisartan Teva Pharma Iceland 6.11.2011 EU/1/11/720/001 Incivo Liechtenstein 31.10.2011 EU/1/11/720/001 Incivo Norway 6.10.2011 EU/1/11/720/001 Incivo 375 mg Filmuhúðuð tafla Iceland 8.10.2011 EU/1/11/728/001-010 Pramipexole Accord Liechtenstein 31.10.2011 EU/1/11/728/001-010 Pramipexole Accord Norway 18.10.2011 EU/1/11/728/001-010 Pramipexole Accord Iceland 10.10.2011 EU/1/11/729/001-006 Onduarp Liechtenstein 31.12.2011 EU/1/11/729/001-006 Onduarp Iceland 14.12.2011 EU/1/11/730/001-060 Rasitrio Norway 7.12.2011 EU/1/11/731/001-012 Komboglyze Liechtenstein 31.12.2011 EU/1/11/731/001-012 Komboglyze Norway 15.12.2011 EU/1/11/731/001-012 Komboglyze Iceland 8.12.2011 EU/1/11/732/001-013 Desloratadine Teva Liechtenstein 31.12.2011 EU/1/11/732/001-013 Desloratadine Teva Norway 20.12.2011 EU/1/11/732/001-013 Desloratadine Teva Iceland 8.12.2011 EU/1/11/733/001-004 Dificlir Liechtenstein 31.12.2011 EU/1/11/733/001-004 Dificlir Norway 20.12.2011 EU/1/11/733/001-004 Dificlir Iceland 14.12.2011 EU/1/11/734/001-011 Edarbi Liechtenstein 31.12.2011 EU/1/11/734/001-011 Edarbi Norway 21.12.2011 EU/1/11/734/001-011 Edarbi Iceland 17.12.2011 EU/1/11/735/001-011 Ipreziv Liechtenstein 31.12.2011 EU/1/11/735/001-011 Ipreziv Norway 21.12.2011 EU/1/11/735/001-011 Ipreziv Iceland 17.12.2011 EU/1/11/736/001 Edurant Liechtenstein 31.12.2011 EU/1/11/736/001 Edurant Norway 6.12.2011 EU/1/11/736/001 EDURANT Iceland 14.12.2011 EU/1/11/737/001-002 Eviplera Liechtenstein 31.12.2011 EU/1/11/737/001-002 Eviplera Norway 6.12.2011 EU/1/11/737/001-002 Eviplera Iceland 14.12.2011 EU/1/11/738/001-003 Levetiracetam Actavis Group Liechtenstein 31.12.2011 EU/1/11/738/001-003 Levetiracetam Actavis Group Iceland 14.12.2011 EU/1/11/739/001-008 Dasselta Liechtenstein 31.12.2011 EU/1/11/739/001-008 Dasselta Iceland 8.12.2011 EU/1/11/740/001 Ameluz Liechtenstein 31.12.2011 EU/2/07/078/011-014 Rheumocam Norway 6.7.2011 EU/2/10/110/001-002 Coxevac Norway 22.8.2011 EU/2/10/112/001-005 BTVPUR AlSap 1 Norway 22.8.2011 EU/2/10/113/001-005 BTVPUR AlSap 1-8 Norway 23.8.2011 EU/2/11/122/001-003 Bluevac BTV8 Iceland 12.7.2011 EU/2/11/124/001-008 Zuprevo Norway 6.7.2011 EU/2/11/125/001-008 Certifect Norway 1.9.2011 EU/2/11/126/001 MS-H-vaksine – Mycoplasma synoviae Norway 5.7.2011 EU/2/11/127/001 Recuvyra Norway 6.12.2011 EU/2/11/127/001 RECUVYRA Iceland 11.11.2011 EU/2/11/128/001-003 Emdocam Norway 14.9.2011 EU/2/11/128/001-003 Emdocam Iceland 8.9.2011 EU/2/11/129/001-004 Proteq West Nile Norway 19.8.2011 EU/2/11/129/001-004 Proteq West Nile Iceland 12.8.2011 EU/2/11/130/001-003 Zulvac 1 Bovis Norway 17.8.2011 EU/2/11/130/001-003 Zulvac 1 Bovis Iceland 18.8.2011 EU/2/11/131/001-006 Zulvac 1 Ovis Norway 17.8.2011 EU/2/11/131/001-006 Zulvac 1 Ovis Iceland 12.8.2011 EU/2/11/132/001-004 Nobivac Myxo-RHD Norway 19.9.2011 EU/2/11/132/001-004 Nobivac Myxo-RHD Iceland 20.9.2011 EU/2/11/133/001-003 Recocam Norway 6.10.2011 EU/2/11/133/001-003 Recocam 20 mg/ml Iceland 23.9.2011 EU/2/11/134/001-014 Inflacam Iceland 19.12.2011 EU/2/11/135/001-003 Panacur AquaSol Iceland 19.12.2011 (1) From the conditional marketing authorisation with a marketing authorisation not subject to specific obligations.

ANNEX II List of renewed marketing authorisations The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July- 31 December 2011: EU-Number Product Country Date of authorisation EU/1/01/196/001 EU/1/01/196/003 Cancidas Norway 20.9.2011 EU/1/01/196/001, 003 Cancidas Iceland 20.9.2011 EU/1/01/196/001, 003 Cancidas Liechtenstein 31.10.2011 EU/1/01/200/001-002 Viread Liechtenstein 31.12.2011 EU/1/06/336/001 Tygacil Iceland 13.7.2011 EU/1/06/340/001-002 Ganfort Liechtenstein 31.8.2011 EU/1/06/340/001-002 Ganfort Norway 1.9.2011 EU/1/06/340/001-002 Ganfort Iceland 8.7.2011 EU/1/06/342/001 Nexavar Liechtenstein 31.8.2011 EU/1/06/342/001 Nexavar Norway 20.9.2011 EU/1/06/342/001 Nexavar Iceland 9.8.2011 EU/1/06/343/001-007 Baraclude Norway 6.7.2011 EU/1/06/346/001 Tysabri Liechtenstein 31.8.2011 EU/1/06/346/001 Tysabri Norway 19.7.2011 EU/1/06/35/001-003 Livensa Liechtenstein 31.8.2011 EU/1/06/350/001 Savene Liechtenstein 31.8.2011 EU/1/06/350/001 Savene Norway 18.8.2011 EU/1/06/350/001 Savene Iceland 9.8.2011 EU/1/06/351/001-003 Livensa Norway 12.8.2011 EU/1/06/351/001-003 Livensa Iceland 9.8.2011 EU/1/06/352/001-003 Intrinsa Liechtenstein 31.8.2011 EU/1/06/352/001-003 Intrinsa Norway 12.8.2011 EU/1/06/352/001-003 Intrinsa Iceland 10.8.2011 EU/1/06/355/001-003 ATryn Liechtenstein 31.8.2011 EU/1/06/355/001-003 ATryn Norway 1.9.2011 EU/1/06/355/001-003 ATryn Iceland 18.8.2011 EU/1/06/356/001-009 Exjade Liechtenstein 31.8.2011 EU/1/06/356/001-009 Exjade Norway 17.8.2011 EU/1/06/356/001-009 Exjade Iceland 9.8.2011 EU/1/06/357/001-008, 018-021 Gardasil Iceland 11.8.2011 EU/1/06/357/001-008 EU/1/06/357/018-021 Gardasil Norway 19.8.2011 EU/1/06/358/001-008, 018-021 Silgard Iceland 10.8.2011 EU/1/06/358/001-021 Silgard Liechtenstein 31.8.2011 EU/1/06/358/001-021 Silgard Norway 12.8.2011 EU/1/06/359/001-004 Suboxone Liechtenstein 31.10.2011 EU/1/06/359/001-004 Suboxone Norway 14.10.2011 EU/1/06/359/001-004 Suboxone Iceland 4.10.2011 EU/1/06/360/001-013 Champix Norway 3.8.2011 EU/1/06/360/001-013 Champix Iceland 7.7.2011 EU/1/06/361/001-002 Luminity Liechtenstein 31.10.2011 EU/1/06/361/001-002 Luminity Norway 21.9.2011 EU/1/06/361/001-002 Luminity Iceland 21.9.2011 EU/1/06/362/001-004 Byetta Liechtenstein 31.10.2011 EU/1/06/362/001-004 Byetta Norway 6.10.2011 EU/1/06/362/001-004 Byetta Iceland 8.10.2011 EU/1/06/363/001-015 Sprycel Liechtenstein 31.10.2011 EU/1/06/363/001-015 Sprycel Norway 14.10.2011 EU/1/06/363/001-015 Sprycel Iceland 7.11.2011 EU/1/06/364/001-004 EU/1/06/364/006-008 Adrovance Norway 23.12.2011 EU/1/06/364/001-004, 006-008 Adrovance Iceland 7.12.2011 EU/1/06/364/006-008 Adrovance Liechtenstein 31.12.2011 EU/1/06/365/001-003 Elaprase Liechtenstein 31.10.2011 EU/1/06/365/001-003 Elaprase Norway 14.10.2011 EU/1/06/365/001-003 Elaprase Iceland 6.11.2011 EU/1/06/368/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088-102, 113-150, 163-168 Insulin Human Winthrop Liechtenstein 31.12.2011 EU/1/06/368/001-168 Insulin Human Winthrop Iceland 6.12.2011 EU/1/06/370/001-039 Exforge Liechtenstein 31.12.2011 EU/1/06/372/001-039 Copalia Liechtenstein 31.12.2011 EU/1/06/372/001-039 Copalia Iceland 7.12.2011 EU/1/06/373/001-039 Imprida Liechtenstein 31.12.2011 EU/1/07/440/001-006 Tyverb Iceland 22.8.2011 EU/1/08/468/001 Intelence Liechtenstein 31.8.2011 EU/1/08/468/001 Intelence Norway 17.8.2011 EU/1/08/468/001 INTELENCE Iceland 11.8.2011 EU/1/09/543/001-002 Cayston Norway 19.9.2011 EU/1/09/543/001-002 Cayston Iceland 19.9.2011 EU/1/10/628/001-004 Votrient Norway 21.10.2011 EU/1/96/024/001-005 Crixivan Liechtenstein 31.8.2011 EU/1/96/024/001-005 EU/1/96/024/010 Crixivan Norway 18.8.2011 EU/1/96/024/001-010 Crixivan Iceland 10.8.2011 EU/2/06/059/001 Convenia Norway 6.7.2011 EU/2/06/060/001-002 Poulvac Flufend H5N3 RG Iceland 11.8.2011 EU/2/06/061/001-004 Nobilis Influenza H5N2 Norway 14.9.2011 EU/2/06/061/001-004 Nobilis Influenza H5N2 Iceland 8.9.2011 EU/2/06/062/001-005 Cerenia Norway 18.8.2011 EU/2/06/062/001-005 Cerenia Iceland 12.8.2011 EU/2/06/064/001-004 ProMeris Norway 8.12.2011 EU/2/06/064/001-004 ProMeris Iceland 21.11.2011 EU/2/06/065/001-010 ProMeris Duo Iceland 4.12.2011 EU/2/06/065/001-010 ProMeris Duo Norway 8.12.2011 EU/2/06/066/001-012 Prac-Tic Norway 8.12.2011 EU/2/06/066/001-012 Prac-tic Iceland 25.11.2011 EU/2/06/069/001 Cortavance Norway 27.9.2011 EU/2/06/069/001 Cortavance Iceland 23.9.2011 EU/2/99/016/001-006 Porcilis Pesti Norway 6.10.2011 EU/2/99/016/001-006 Porcilis Pesti Iceland 7.10.2011

ANNEX III List of extended marketing authorisations The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July- 31 December 2011: EU-Number Product Country Date of authorisation EU/1/00/165/008 Ovitrelle Liechtenstein 31.8.2011 EU/1/00/165/008 Ovitrelle Norway 6.7.2011 EU/1/01/176/007-009 Zometa Liechtenstein 31.10.2011 EU/1/01/176/007-009 Zometa Norway 12.9.2011 EU/1/01/176/007-009 Zometa Iceland 12.11.2011 EU/1/02/221/011-016 Pegasys Liechtenstein 31.8.2011 EU/1/03/248/013-023 Levitra Liechtenstein 31.12.2011 EU/1/03/249/013-015 Vivanza Liechtenstein 31.12.2011 EU/1/03/260/034-038 Stalevo Norway 23.9.2011 EU/1/03/260/034-038 Stalevo Liechtenstein 31.10.2011 EU/1/03/260/034-038 Stalevo Iceland 13.9.2011 EU/1/03/262/009-010 Emend Liechtenstein 31.12.2011 EU/1/03/270/004-005 Kentera Liechtenstein 31.8.2011 EU/1/03/270/004-005 Kentera Norway 7.9.2011 EU/1/03/270/004-005 Kentera Iceland 9.9.2011 EU/1/03/271/007-010 Advate Liechtenstein 31.12.2011 EU/1/05/322/002 Yttriga Liechtenstein 31.8.2011 EU/1/06/332/010-012 Omnitrope Norway 25.8.2011 EU/1/06/378/017 Inovelon Liechtenstein 31.12.2011 EU/1/06/378/017 Inovelon Norway 20.12.2011 EU/1/07/392/003 Circadin Liechtenstein 31.10.2011 EU/1/07/401/016 Alli Liechtenstein 31.8.2011 EU/1/07/422/007-008 Tasigna Liechtenstein 31.8.2011 EU/1/07/422/009-012 Tasigna Liechtenstein 31.12.2011 EU/1/08/442/009-013 Pradaxa Iceland 10.8.2011 EU/1/08/442/009-014 Pradaxa Liechtenstein 31.8.2011 EU/1/08/442/009-014 Pradaxa Norway 17.8.2011 EU/1/08/468/002 Intelence Liechtenstein 31.12.2011 EU/1/08/468/002 Intelence Norway 15.12.2011 EU/1/08/470/014-015 Vimpat Iceland 8.12.2011 EU/1/08/472/011-021 Xarelto Liechtenstein 31.12.2011 EU/1/08/472/011-021 Xarelto Iceland 20.12.2011 EU/1/09/508/011 Synflorix Liechtenstein 31.8.2011 EU/1/09/531/010-021 Instanyl Liechtenstein 31.8.2011 EU/1/09/531/010-021 Instanyl Norway 1.8.2011 EU/1/09/531/010-021 Instanyl Iceland 13.7.2011 EU/1/09/564/003 Ilaris Liechtenstein 31.10.2011 EU/1/09/564/003 Ilaris Iceland 5.10.2011 EU/1/09/564/003 Ilaris Norway 27.9.2011 EU/1/09/610/031-060 Telmisartan Teva Liechtenstein 31.8.2011 EU/1/10/614/003 Menveo Liechtenstein 31.8.2011 EU/1/10/636/004-007 Daxas Liechtenstein 31.12.2011 EU/1/10/646/003-006 VPRIV Liechtenstein 31.8.2011 EU/1/10/647/003-004 Myclausen Norway 27.9.2011 EU/1/10/647/003-004 Myclausen Iceland 3.10.2011 EU/1/95/003/011-012 Betaferon Liechtenstein 31.8.2011 EU/1/97/055/005-009 Viramune Norway 14.10.2011 EU/1/97/055/005-009 Viramune Iceland 5.10.2011 EU/1/98/090/021-022 Micardis Liechtenstein 31.8.2011 EU/1/99/119/019-023 NovoRapid Liechtenstein 31.8.2011 EU/1/99/126/022 Enbrel Iceland 13.7.2011 EU/2/08/090/010-018 Loxicom Norway 15.8.2011 EU/2/08/090/010-026 Loxicom Iceland 22.7.2011 EU/2/08/090/019-026 Loxicom Norway 27.9.2011

ANNEX IV List of withdrawn marketing authorisations The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July- 31 December 2011: EU-Number Product Country Date of withdrawal EU/1/02/225/001-002 Xigris Liechtenstein 31.12.2011 EU/1/03/259/001-006 Onsenal Norway 5.8.2011 EU/1/05/313/001-009 Ablavar Liechtenstein 31.10.2011 EU/1/05/313/001-009 Ablavar Norway 29.11.2011 EU/1/05/313/001-009 Ablavar Iceland 6.11.2011 EU/1/08/470/014-015 Vimpat Iceland 8.12.2011 EU/1/08/478/001 Prepandemic influenza vaccine (H5N1) Liechtenstein 31.10.2011 EU/1/08/478/001 Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals Iceland 6.11.2011 EU/1/09/547/001-007 Clopidogrel Sandoz Norway 5.8.2011 EU/1/09/547/001-007 Clopidogrel Sandoz Iceland 23.8.2011 EU/1/10/629/001 Humenza Norway 5.8.2011 EU/2/06/063/001-003 Yarvitan Norway 22.9.2011 EU/2/06/063/001-003 Yarvitan Iceland 26.8.2011 EU/1/06/349/001-010 Avaglim Norway 18.8.2011